CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 13 enrolled
Drug / intervention
Sodium ferric gluconatedrug
Likely dose
Sodium ferric gluconate 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01925703
NCT01925703Phase 4Completed
CompareCT.gov

Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure

University of North Carolina, Chapel Hill·interventional·Posted Aug 20, 2013·Updated Aug 25, 2015

In Brief

A Phase 4 clinical trial evaluating Sodium ferric gluconate for Heart Failure and Iron Deficiency Anemia. Completed, enrolled 13 participants across 1 site.

Detailed Summary

Intravenous iron replacement has been shown to benefit patients with heart failure and iron deficiency, but the weekly outpatient regimens studied to date are impractical for many patients. Our purpose is to evaluate the short-term effects and safety of an accelerated intravenous iron regimen in hospitalized patients with these two conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Iron Deficiency Anemia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 20, 2013
Enrollment StartApr 1, 2011
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 12.9 years ago

Interventions

Sodium ferric gluconatedrug

Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.